Company Description
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.
It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial.
The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2014 |
| IPO Date | May 5, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Margaret Alexander |
Contact Details
Address: 441 Ninth Avenue, 14th Floor New York, New York 10001 United States | |
| Phone | 646 661 7661 |
| Website | ovidrx.com |
Stock Details
| Ticker Symbol | OVID |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001636651 |
| CUSIP Number | 690469101 |
| ISIN Number | US6904691010 |
| Employer ID | 46-5270895 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Margaret Alexander | Chief Executive Officer, President and Chief Operating Officer |
| Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | Co-Founder and Executive Chairman |
| Jeffrey A. Rona | Chief Business and Financial Officer and Corporate Secretary |
| Dr. Zhong Zhong Ph.D. | Chief Scientific Officer |
| Dr. Julia Tsai Ph.D. | Senior Vice President of Clinical Development |
| Dr. Toshiya Nishi D.V.M. | Head of Epilepsy Research |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Chief Regulatory Officer |
| Victoria Fort | Senior Vice President of Corporate Affairs and Corporate Strategy |
| Charles Ross Carter | Senior Vice President of Finance and Financial Planning |
| Dr. Petra Kaufmann M.D., M.S. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Jan 29, 2026 | SCHEDULE 13G/A | Filing |
| Jan 8, 2026 | SCHEDULE 13G | Filing |
| Jan 5, 2026 | SCHEDULE 13G | Filing |
| Dec 22, 2025 | EFFECT | Notice of Effectiveness |
| Dec 22, 2025 | 424B3 | Prospectus |
| Dec 18, 2025 | SCHEDULE 13G | Filing |
| Dec 18, 2025 | SCHEDULE 13G | Filing |
| Dec 18, 2025 | 8-K | Current Report |
| Dec 15, 2025 | S-3 | Registration statement under Securities Act of 1933 |